MediClin AG (STU:MED) Other Financing: €-73.1 Mil (TTM As of Mar. 2026)


STU:MED MediClin AG STU:MED
76 GF Score
Price €3.90
GF Value €2.93
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is MediClin AG Other Financing?

MediClin AG STU:MED +0.52% 76 Other Financing is €-73.1 Mil as of Mar. 2026. GuruFocus rates STU:MED with a GF Score™ of 76/100 and a GF Value™ of €2.93 (Significantly Overvalued). The stock has 5 warning signs investors should review.

MediClin AG's Other Financing for the three months ended in Mar. 2026 was €-4.8 Mil.

MediClin AG's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €-73.1 Mil.

MediClin AG Other Financing Historical Data

* Premium members only.

The historical data trend for MediClin AG's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediClin AG Other Financing Chart

MediClin AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.26 -11.94 -23.44 -49.07 -72.51

MediClin AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.11 -6.98 -5.86 -55.46 -4.84
STU:MED
76GF Score
MediClin AG STU:MED
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediClin AG Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-73.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €-73.1 Mil mean?
MediClin AG (STU:MED) has a Other Financing of €-73.1 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for MediClin AG and its competitors.
Is MediClin AG's Other Financing too high?
MediClin AG's current Other Financing is €-73.1 Mil. Overall, MediClin AG has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's Other Financing compare to HCA and THC?
MediClin AG's Other Financing of €-73.1 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Healthcare Providers & Services company?
A good Other Financing depends on the Healthcare Providers & Services industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for MediClin AG and its competitors. MediClin AG's current Other Financing is €-73.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (STU:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.93, compared to a current price of €3.90 — trading 33.1% above its estimated fair value. The current Other Financing is €-73.1 Mil. MediClin AG's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For MediClin AG (STU:MED), the current Other Financing is €-73.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MediClin AG (STU:MED) Overvalued in 2026?

Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued. The current stock price of €3.90 is trading 33.1% above its estimated GF Value™ of €2.93. GuruFocus considers MediClin AG to be Significantly Overvalued.

Key valuation signals for STU:MED:

  • Other Financing: €-73.1 Mil
  • GF Value™: €2.93 vs. price of €3.90 (33.1% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the STU:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediClin AG Business Description

Other Exchanges 0NDG:UKMED:Germany
Address Okenstrasse 27, Offenburg, BW, DEU, 77652
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
76GF Score

Get the complete analysis for STU:MED

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.90
Price
€2.93
GF Value